

# Xingxing Zang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/181742/publications.pdf>

Version: 2024-02-01

92  
papers

7,734  
citations

61984

43  
h-index

53230

85  
g-index

97  
all docs

97  
docs citations

97  
times ranked

9530  
citing authors

#	ARTICLE	IF	CITATIONS
1	Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. <i>Genes and Diseases</i> , 2022, 9, 1181-1193.	3.4	8
2	The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development. <i>Science Advances</i> , 2022, 8, eabm7012.	10.3	13
3	The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy. <i>Nature Communications</i> , 2022, 13, 2506.	12.8	18
4	MEDB-76. Evaluating the B7-H3 checkpoint in Medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i124-i124.	1.2	0
5	PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies. <i>Trends in Molecular Medicine</i> , 2021, 27, 207-219.	6.7	23
6	LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 606-613.	1.3	13
7	B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2021, 28, 135-149.	3.1	15
8	Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 2636-2647.	7.0	140
9	B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 161-169.	2.3	13
10	KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. <i>Science Immunology</i> , 2021, 6, .	11.9	39
11	B7 score and T cell infiltration stratify immune status in prostate cancer. , 2021, 9, e002455.		16
12	Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNF $\alpha$ . <i>Blood Advances</i> , 2021, 5, 3592-3608.	5.2	17
13	Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting. <i>Stem Cell Investigation</i> , 2021, 8, 18-18.	3.0	12
14	Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer. <i>Cell Death and Disease</i> , 2020, 11, 753.	6.3	15
15	Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 280.	3.7	28
16	HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis. <i>British Journal of Cancer</i> , 2020, 122, 1211-1218.	6.4	26
17	Prognostic Factors for North American Adult T Cell Leukemia Lymphoma: Defining Risk Groups Using a Four-Point Score Prognostic System. <i>Blood</i> , 2020, 136, 38-39.	1.4	0
18	Dynamics of Leukocyte Subpopulations Reconstitution Predict Infection Propensity in a Multiethnic Real World Cohort Treated with Anti-CD19 CAR-T Cell Therapy (Axicabtagene-Ciloleucel). <i>Blood</i> , 2020, 136, 10-11.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Tumor Cholesterol Up, T Cells Down. <i>Cell Metabolism</i> , 2019, 30, 12-13.	16.2	11
20	The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 883-896.	8.7	37
21	Blockade of CTLA-4 and Tim-3 pathways induces fetal loss with altered cytokine profiles by decidual CD4 <sup>+</sup> T cells. <i>Cell Death and Disease</i> , 2019, 10, 15.	6.3	33
22	Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. <i>Blood</i> , 2019, 134, 1406-1414.	1.4	80
23	Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway. <i>Journal of Cellular Physiology</i> , 2019, 234, 22400-22410.	4.1	20
24	Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. <i>Cells</i> , 2019, 8, 618.	4.1	14
25	The appropriate frequency and function of decidual Tim-3+CTLA-4+CD8 <sup>+</sup> T cells are important in maintaining normal pregnancy. <i>Cell Death and Disease</i> , 2019, 10, 407.	6.3	47
26	Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 59.	17.0	127
27	Human urothelial bladder cancer generates a clonal immune response: The results of T-cell receptor sequencing. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 810.e1-810.e5.	1.6	3
28	PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 3589-3601.	7.0	16
29	Identification of chimeric RNAs in human infant brains and their implications in neural differentiation. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 111, 19-26.	2.8	6
30	Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models. <i>Cellular and Molecular Immunology</i> , 2019, 16, 908-920.	10.5	131
31	Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model. <i>Bladder Cancer</i> , 2019, 5, 63-71.	0.4	9
32	The TRIM protein Mitsugumin 53 enhances survival and therapeutic efficacy of stem cells in murine traumatic brain injury. <i>Stem Cell Research and Therapy</i> , 2019, 10, 352.	5.5	40
33	Structures of Immune Checkpoints: An Overview on the CD28-B7 Family. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1172, 63-78.	1.6	15
34	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. <i>JCI Insight</i> , 2019, 4, .	5.0	8
35	PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers. <i>Oncolmmunology</i> , 2018, 7, e1433520.	4.6	31
36	NF- $\kappa$ B RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8 <sup>+</sup> T cells for tumor promotion. <i>Oncolmmunology</i> , 2018, 7, e1435250.	4.6	29

#	ARTICLE	IF	CITATIONS
37	Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1 <sup>+</sup> Negative Human Lung Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 1954-1964.	7.0	64
38	An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 611-619.	1.2	22
39	The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 459-468.	1.6	8
40	2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade <sup>â€</sup> A personal account. <i>Genes and Diseases</i> , 2018, 5, 302-303.	3.4	32
41	HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 498.	3.7	27
42	The third group of the B7 <sup>â€</sup> CD <sup>28</sup> immune checkpoint family: <sup>â€</sup> HHLA <sup>2</sup> , <sup>â€</sup> TMIGD <sup>2</sup> , B7x, and B7 <sup>â€</sup> H3. <i>Immunological Reviews</i> , 2017, 276, 26-39.	6.0	185
43	A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment 1 1MPS is an investor in and consultant for Urogen. SAP is consultant and advisor for Vaccinex. The remaining authors have nothing to disclose.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 14-20.	1.6	67
44	HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. <i>Clinical Cancer Research</i> , 2017, 23, 825-832.	7.0	78
45	Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells. <i>Oncotarget</i> , 2017, 8, 82740-82753.	1.8	17
46	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. <i>Immunotherapy</i> , 2016, 8, 809-819.	2.0	44
47	Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 3425-3431.	7.0	368
48	HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. <i>Scientific Reports</i> , 2016, 6, 31154.	3.3	69
49	Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?. <i>Immunological Investigations</i> , 2016, 45, 813-831.	2.0	21
50	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. <i>Scientific Reports</i> , 2016, 6, 30093.	3.3	213
51	B7-H4(B7x) <sup>â€</sup> Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 2778-2790.	7.0	128
52	Tumor Infiltrating Lymphocytes as a Prognostic and Predictive Biomarker in Breast Cancer. , 2016, , 167-186.		0
53	New immunotherapies targeting the PD-1 pathway. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 587-595.	8.7	158
54	Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. <i>Clinical Cancer Research</i> , 2015, 21, 2359-2366.	7.0	125

#	ARTICLE	IF	CITATIONS
55	HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. <i>Oncolmunology</i> , 2015, 4, e1026534.	4.6	93
56	Substituting Threonine 187 with Alanine in p27Kip1 Prevents Pituitary Tumorigenesis by Two-Hit Loss of Rb1 and Enhances Humoral Immunity in Old Age. <i>Journal of Biological Chemistry</i> , 2015, 290, 5797-5809.	3.4	10
57	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. <i>Immunotherapy</i> , 2015, 7, 1169-1186.	2.0	45
58	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. <i>Trends in Molecular Medicine</i> , 2015, 21, 24-33.	6.7	628
59	Structure and Cancer Immunotherapy of the B7 Family Member B7x. <i>Cell Reports</i> , 2014, 9, 1089-1098.	6.4	58
60	Tissue-Expressed B7-H1 Critically Controls Intestinal Inflammation. <i>Cell Reports</i> , 2014, 6, 625-632.	6.4	53
61	Structure and T Cell Inhibition Properties of B7 Family Member, B7-H3. <i>Structure</i> , 2013, 21, 707-717.	3.3	92
62	Host B7x Promotes Pulmonary Metastasis of Breast Cancer. <i>Journal of Immunology</i> , 2013, 190, 3806-3814.	0.8	59
63	B7x and myeloid-derived suppressor cells in the tumor microenvironment. <i>Oncolmunology</i> , 2013, 2, e24744.	4.6	21
64	Curcumin improves the therapeutic efficacy of <i>Listeria</i> vaccine in correlation with improved T cell responses in blood of a triple-negative breast cancer model 4T1. <i>Cancer Medicine</i> , 2013, 2, 571-582.	2.8	62
65	HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9879-9884.	7.1	160
66	B7x in the Periphery Abrogates Pancreas-Specific Damage Mediated by Self-reactive CD8 T Cells. <i>Journal of Immunology</i> , 2012, 189, 4165-4174.	0.8	29
67	Tissue-Expressed B7x Affects the Immune Response to and Outcome of Lethal Pulmonary Infection. <i>Journal of Immunology</i> , 2012, 189, 3054-3063.	0.8	19
68	T cell coinhibition and immunotherapy in human breast cancer. <i>Discovery Medicine</i> , 2012, 14, 229-36.	0.5	28
69	T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. <i>Trends in Molecular Medicine</i> , 2011, 17, 47-55.	6.7	44
70	Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. <i>Journal of Experimental Medicine</i> , 2011, 208, 1683-1694.	8.5	54
71	The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	118
72	T cell costimulation and coinhibition: genetics and disease. <i>Discovery Medicine</i> , 2011, 12, 119-28.	0.5	21

#	ARTICLE	IF	CITATIONS
73	Mouse Mast Cell Protease-4 Deteriorates Renal Function by Contributing to Inflammation and Fibrosis in Immune Complex-Mediated Glomerulonephritis. <i>Journal of Immunology</i> , 2010, 185, 624-633.	0.8	64
74	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. <i>Modern Pathology</i> , 2010, 23, 1104-1112.	5.5	204
75	The contrasting role of B7-H3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10277-10278.	7.1	157
76	Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage. <i>Cancer Research</i> , 2008, 68, 6054-6058.	0.9	71
77	Alternative Activation Is an Innate Response to Injury That Requires CD4+ T Cells to be Sustained during Chronic Infection. <i>Journal of Immunology</i> , 2007, 179, 3926-3936.	0.8	230
78	B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19458-19463.	7.1	336
79	T Cell Immunoglobulin Mucin-3 Crystal Structure Reveals a Galectin-9-Independent Ligand-Binding Surface. <i>Immunity</i> , 2007, 26, 311-321.	14.3	183
80	The B7 Family and Cancer Therapy: Costimulation and Coinhibition. <i>Clinical Cancer Research</i> , 2007, 13, 5271-5279.	7.0	308
81	A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. <i>Genomics</i> , 2006, 88, 841-845.	2.9	12
82	To be or not to be B7. <i>Journal of Clinical Investigation</i> , 2006, 116, 2590-2593.	8.2	20
83	Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9872-9877.	7.1	21
84	BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. <i>Nature Immunology</i> , 2003, 4, 670-679.	14.5	768
85	B7x: A widely expressed B7 family member that inhibits T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10388-10392.	7.1	362
86	Homologues of Human Macrophage Migration Inhibitory Factor from a Parasitic Nematode. <i>Journal of Biological Chemistry</i> , 2002, 277, 44261-44267.	3.4	99
87	Cloning and characterisation of mmc-1, a microfilarial-specific gene, from <i>Brugia pahangi</i> . <i>International Journal for Parasitology</i> , 2002, 32, 415-424.	3.1	5
88	Immune evasion genes from filarial nematodes. <i>International Journal for Parasitology</i> , 2001, 31, 889-898.	3.1	158
89	Serine proteinase inhibitors from nematodes and the arms race between host and pathogen. <i>Trends in Biochemical Sciences</i> , 2001, 26, 191-197.	7.5	136
90	<i>Brugia malayi</i> Homolog of Macrophage Migration Inhibitory Factor Reveals an Important Link Between Macrophages and Eosinophil Recruitment During Nematode Infection. <i>Journal of Immunology</i> , 2001, 167, 5348-5354.	0.8	121

#	ARTICLE	IF	CITATIONS
91	The Serpin Secreted by <i>Brugia malayi</i> Microfilariae, Bm-SPN-2, Elicits Strong, but Short-Lived, Immune Responses in Mice and Humans. <i>Journal of Immunology</i> , 2000, 165, 5161-5169.	0.8	61
92	A Novel Serpin Expressed by Blood-Borne Microfilariae of the Parasitic Nematode <i>Brugia malayi</i> Inhibits Human Neutrophil Serine Proteinases. <i>Blood</i> , 1999, 94, 1418-1428.	1.4	114